RBC

RUSSEL METALS ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS

Retrieved on: 
Tuesday, January 2, 2024
CPA, Business administration, RBC Dominion Securities, Retirement, RBC, MBA, RBC Capital Markets, University, Harvard University, TSX, Metal, Russel Metals, Management

TORONTO, Jan. 2, 2024 /PRNewswire/ - Russel Metals Inc. (TSX: RUS) announces the retirement of Linh Austin from the Board of Directors and the appointment of Stewart Burton as an independent Director.

Key Points: 
  • TORONTO, Jan. 2, 2024 /PRNewswire/ - Russel Metals Inc. (TSX: RUS) announces the retirement of Linh Austin from the Board of Directors and the appointment of Stewart Burton as an independent Director.
  • Russel Metals' Board Chair Jim Dinning extended his appreciation for Mr. Austin's service and commented "I want to thank Linh for his contributions to our Board and wish him well."
  • Jim Dinning commented, "We welcome Stewart Burton to Russel Metals.
  • Stewart's extensive business experience and his deep knowledge of global capital markets will add to the strength of our Board of Directors and be a benefit to shareholders.

Reliq Health Technologies, Inc. Announces the Appointment of Directors

Retrieved on: 
Friday, December 15, 2023
Quality of life, Barrie—Springwater—Oro-Medonte, RHT, Municipality, TSX Venture Exchange, Health care, Government, Marketing, TMX Group, WKN, RBC, MBA, Chemical engineering, Frankfurt Stock Exchange, University, Meridian Credit Union, Medicare, Economic development, Person, Interim, Medicaid, Municipal council, Customer service, Patient, Babson College, Digital economy, OTC, Parliament, Management

First elected as a City Councillor in Barrie, in 2006, Alex continued to serve at the Municipal level of government until 2014.

Key Points: 
  • First elected as a City Councillor in Barrie, in 2006, Alex continued to serve at the Municipal level of government until 2014.
  • “We are pleased to welcome Alex and Chris as new directors,” said Brian Storseth, director of the Company.
  • Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.
  • Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, December 11, 2023
Patient, Quality of life, Erythropoietin, Protein, Exposition, Fever, Reticulocyte, Homeostasis, Bone marrow, MF, IWG, Haematopoiesis, Research, Erythropoiesis, Diarrhea, Anemia, KROS, Fatigue, Nausea, Headache, RBC, Iron overload, Society, MDS, Therapy, Weakness, Ruxolitinib, Thrombocytopenia, ASH, TI, Week, Periodic breathing, MBBS, Biomarker, Safety, Acute myeloid leukemia, HTB, Cytopenia, Disorder, Pharmaceutical industry

“Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.

Key Points: 
  • “Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
  • Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients.
  • All data presented from this trial is as of the data cut-off date.
  • 13 of those 18 patients (72.2%) achieved TI for at least 24 weeks over the first 48 weeks of treatment.

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Cellular, Transplant, NPM1, Drug resistance, CD34, Exposition, STAT5, Bone marrow, Phosphorylation, RBC, CD71, Society, Therapy, MDS, Pharmacology, Ruxolitinib, ASH, Mutation, Coactivator (genetics), STAT1, Meeting, Syndrome, PST, Glycophorin A, Webcast, Patient, Safety, Acute myeloid leukemia, RVU, AML, DNA (cytosine-5)-methyltransferase 3A, Pharmaceutical industry

Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.

Key Points: 
  • Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
  • The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.
  • KRAKOW, Poland, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.
  • “The results from the CLI120-001 (RIVER-51) study of RVU120 in patients with r/r-AML and HR-MDS continue to improve over time.

Apollo Adds ELTIF to Wealth Product Platform Following CSSF Regulatory Approval

Retrieved on: 
Monday, December 11, 2023
ACT, Infrastructure, S64, Sale, APO, Sustainability, RBC, CSSF, Equity, Climate change

LUXEMBOURG, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced the Apollo Clean Transition Equity ELTIF (“ACT Equity ELTIF” or the “Fund”) will launch via Apollo Private Markets SICAV, the firm’s Luxembourg-based product platform, after receiving regulatory authorization from Luxembourg’s Commission de Surveillance du Secteur Financier (CSSF)1. ACT Equity ELTIF is designed to offer wealth investors across Europe greater access to private equity opportunities focused on the transition to clean energy and sustainable industry.

Key Points: 
  • LUXEMBOURG, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced the Apollo Clean Transition Equity ELTIF (“ACT Equity ELTIF” or the “Fund”) will launch via Apollo Private Markets SICAV, the firm’s Luxembourg-based product platform, after receiving regulatory authorization from Luxembourg’s Commission de Surveillance du Secteur Financier (CSSF)1.
  • ACT Equity ELTIF is designed to offer wealth investors across Europe greater access to private equity opportunities focused on the transition to clean energy and sustainable industry.
  • The addition of ACT Equity ELTIF to the Apollo Private Markets platform furthers Apollo’s commitment to provide individual investors institutional-quality managed products through its Global Wealth business.
  • Through Apollo Private Markets SICAV’s structure, ACT Equity ELTIF will be accessible to European investors in their local currency and will be fully funded at launch.

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

Retrieved on: 
Wednesday, December 6, 2023
Phase, Patient, EVH, Food, Immune system, Physician, FDA, Haematopoietic system, Anemia, Blood, PNH, RBC, City, MD, Novartis, Hematology, MRCP, IVH, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry

Approval was also supported by the Phase III APPOINT-PNH study in complement inhibitor-naïve patients1,3.

Key Points: 
  • Approval was also supported by the Phase III APPOINT-PNH study in complement inhibitor-naïve patients1,3.
  • Patients with sustained hemoglobin level ≥ 12 g/dLa in the absence of transfusions: 67.7% of anti-C5-experienced Fabhalta patients responded vs. 0% for anti-C5 (difference of 66.6%b, P
  • Patients avoiding transfusiond,e: Transfusion avoidance rate 95.2% for anti-C5-experienced Fabhalta patients vs. 45.7% for anti-C5 (difference of 49.5%b, P
  • In APPOINT-PNH, serious ARs were reported in two (5%) patients with PNH receiving Fabhalta, which included COVID-19 and bacterial pneumonia1,3.

NOVA CHEMICALS CORPORATION ANNOUNCES EARLY TENDER RESULTS OF CASH TENDER OFFER FOR ITS 4.875% SENIOR NOTES DUE 2024

Retrieved on: 
Monday, November 27, 2023
Tender offer, Latham & Watkins, RBC, RBC Capital Markets, Toll, NOVA, Settlement, Tender, Torys, Date, Capital market, Nova Chemicals, Cryptocurrency

The Aggregate Maximum Principal Amount has been fully subscribed by the Notes tendered as of the Early Tender Date.

Key Points: 
  • The Aggregate Maximum Principal Amount has been fully subscribed by the Notes tendered as of the Early Tender Date.
  • NOVA Chemicals does not anticipate accepting for purchase any Notes validly tendered after the Early Tender Date.
  • NOVA Chemicals is making the Tender Offer only in those jurisdictions where it is legal to do so.
  • Copies of the Offer to Purchase are available to holders of Notes from Global Bondholder Services Corporation, the information and tender agent for the Tender Offer.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Wednesday, December 20, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Patient, Specialty pharmacy, Bone marrow failure, Immune system, Pharmacy, Thrombosis, Blood, Hemolysis, PNH, RBC, Novartis, Mutation, Medication, Paroxysmal nocturnal hemoglobinuria

“Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.

Key Points: 
  • “Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.
  • Every year, roughly 500 patients in the U.S. are diagnosed with PNH.3 An estimated 10-16 cases per million patients around the world have PNH.
  • Most patients are diagnosed with PNH in their 30s and 40s.
  • Please see the full Prescribing Information for Fabhalta, including Boxed WARNING and Medication Guide.®

 Capstone Copper Announces Commissioning Activities Underway at MVDP and Provides Corporate Update

Retrieved on: 
Thursday, December 21, 2023
Natural Resources, Other Natural Resources, Mining, Minerals, Workforce, Australian Securities Exchange, ASX, Multimedia, CS, Retirement, RBC, MBA, RBC Capital Markets, Element, Ausenco, Growth, TSX, Toronto Stock Exchange, Metal, Security (finance)

Capstone Copper Corp. (“Capstone” or the “Company”) (TSX:CS) is pleased to announce that commissioning activities are underway at its Mantoverde Development Project (“MVDP”) in Chile.

Key Points: 
  • Capstone Copper Corp. (“Capstone” or the “Company”) (TSX:CS) is pleased to announce that commissioning activities are underway at its Mantoverde Development Project (“MVDP”) in Chile.
  • The Company is focused on a safe, efficient and phased project commissioning and ramp-up.
  • MVDP will increase the Company’s consolidated copper production by over 40% with a significant decrease in unit operating costs.
  • Mr. Bell has global expertise in corporate strategy, debt and equity financing, shareholder engagement, and mergers and acquisitions.